Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Focus on fat deposits that are difficult to reduce through diet and exercise alone
Dose frequency should relate to the severity of the deficiency
AOD-9604 failed Phase 2 not due to safety concerns but because the magnitude of fat loss versus placebo, while statistically significant, was too modest to meet the efficacy threshold for a standalone obesity treatment
The promise is real, but clinical readiness is not: Preclinical and early human data are compelling, but without large-scale trials, validated delivery methods, and long-term safety data, Epitalon remains an experimental peptide, one to watch closely, but not yet ready for mainstream clinical adoption
A tripeptide affecting 6% of the human genome
US$ 20.07
US$ 21.61
US$ 22.53
US$ 21.86
